Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
Year: 2017
Type: article
Authors: Akio Ohta, Hiroyuki Kato, Satoshi Ishii, Yosuke Sasaki, Yuta Nakamura, Tomoko Nakagawa, Yoshio Nagai, Yasushi Tanaka
Institution: St. Marianna University School of Medicine
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2743468233
